Insurance Coverage for Ketamine Tablet

Why Ketamine Insurance Claim Denial Happens

A ketamine insurance claim denial almost always comes down to two factors working together: the drug is being prescribed off-label, and it's dispensed as a compounded medication. No ketamine tablet formulation carries FDA approval for depression, anxiety, PTSD, or chronic pain, and compounded preparations are generally excluded from pharmacy formularies regardless of indication. Together, these two facts explain why most commercial insurers deny coverage for compounded ketamine tablet under the pharmacy benefit. Coverage isn't impossible, though. Some patients recover partial costs through pain-indication billing, out-of-network mental health benefits, or a formal appeal. This guide explains why denials happen, the billing codes involved, and the steps to challenge a denial or find a workable coverage pathway.

The Off-Label and Compounded Problem

Two structural issues combine to make ketamine tablet coverage difficult.

Off-label use. No ketamine tablet formulation has FDA approval for depression, anxiety, PTSD, or chronic pain. Insurers typically require FDA approval, or comparable substantial evidence, before covering a drug for a specific indication. Esketamine (brand name Spravato), a nasal spray chemically related to ketamine, does have FDA approval for treatment-resistant depression, which is why its coverage picture looks different from compounded ketamine tablet's. See our overview of FDA considerations for ketamine tablet for more on this distinction.

Compounded preparation. A compounded drug is a medication mixed or prepared by a pharmacy to meet an individual prescription, rather than manufactured and approved as a finished product by the FDA. According to the FDA, compounded drugs are not FDA-approved, meaning they haven't gone through the agency's premarket review for safety, effectiveness, and manufacturing quality. Insurance formularies are built around FDA-approved drugs, so compounded preparations are routinely excluded no matter the indication. Our guide to compounded ketamine tablets covers how these preparations are made and regulated.

Together, these two barriers mean most commercial insurers will not cover compounded ketamine tablet for psychiatric indications under the pharmacy benefit. That's the root cause behind most ketamine insurance claim denials patients report.

Pathways to Partial Coverage

Despite the general rule, several pathways can produce at least partial coverage.

Pain Indications Billed Under the Medical Benefit

For chronic pain conditions, some insurers cover ketamine under the medical benefit rather than the pharmacy benefit, when the indication has recognized clinical use, the claim is submitted as a procedure rather than a drug claim, the prescriber documents medical necessity, and the pain condition has been refractory to standard treatments. Complex Regional Pain Syndrome (CRPS), a chronic pain condition that typically develops after an injury to a limb, is the diagnosis where ketamine coverage is most commonly approved; some private insurers and Medicaid plans have specific coverage policies for ketamine in CRPS. Patients pursuing this route should ask their prescriber to document diagnosis and treatment history, submit the claim under appropriate medical procedure codes, and include a letter of medical necessity emphasizing the refractory nature of the pain. Workers' compensation claims involving ketamine follow a related but separate process; see our coverage of ketamine and workers' comp coverage for an example.

Out-of-Network Mental Health Benefit for Visits

The ketamine drug cost is rarely covered, but prescriber visit costs, meaning the evaluation and monitoring appointments, may be reimbursed under an out-of-network mental health benefit depending on the plan. Federal parity rules require that out-of-network mental health benefits not be more restrictive than out-of-network medical benefits, so partial reimbursement for visits is possible even when the ketamine itself isn't covered.

Mental Health Parity Act Considerations

The Mental Health Parity and Addiction Equity Act (MHPAEA) is a federal law requiring that health plans covering mental health treatment apply financial requirements and treatment limitations no more restrictive than those used for comparable medical benefits. According to the U.S. Department of Labor, group health plans that offer mental health or substance use disorder benefits alongside medical and surgical benefits must apply parity between the two. If an insurer covers other off-label psychiatric drugs, which most do for established uses, some patient advocates and attorneys argue that denying ketamine tablet coverage for treatment-resistant depression could conflict with parity requirements. This is a complex legal argument, best pursued with a patient advocate or an attorney who focuses on insurance law, and outcomes vary by case and plan.

Combination Approach

In many practical situations, the most achievable outcome is a hybrid one: insurance covers the prescriber visit (evaluation, monitoring, follow-up), while the patient pays out-of-pocket for the ketamine tablet itself, often using FSA or HSA funds to offset the cost.

Relevant Billing Codes

Understanding billing codes helps when communicating with insurers about coverage and when evaluating claims for accuracy.

Prescriber Visit Codes (Evaluation and Management)

99213 or 99214 cover established-patient office visits for psychiatric evaluation and follow-up. 90792 covers a psychiatric diagnostic evaluation with medical services. 90863 covers pharmacologic management, either standalone or as an add-on. These codes apply to the clinical visit component regardless of whether ketamine is being prescribed.

Ketamine Drug Claims Under the Medical Benefit

Drugs administered in a physician's office or clinic can be billed with HCPCS codes under the medical benefit, but compounded drugs often have no HCPCS code assigned, which complicates billing. Ketamine tablet specifically has no standard HCPCS code for the oral formulation. Some practices use NDC (National Drug Code) billing for compounded drugs instead, though insurer acceptance varies.

Spravato-Specific Codes

Spravato (esketamine), the FDA-approved nasal spray, uses a different billing path than compounded ketamine tablet. Practices may use J3490 or J3590, unclassified drug codes, until a specific J-code is assigned, along with 99213/99214 combined with G2086 for the administration and monitoring visit. Confirm current code assignment with the prescribing clinic, since drug-specific codes are updated periodically.

Preparing a Coverage Request

For any coverage request, thorough documentation matters. Prescribers should include a full treatment history covering all prior antidepressant or pain medication trials, specific dates, doses, and reasons for discontinuation of each, clinical notes documenting functional impairment from the condition, and a letter of medical necessity explaining why ketamine is indicated and why other options have been exhausted.

Using FSA or HSA Funds for Remaining Costs

For drug costs insurance won't cover, FSA and HSA funds provide a tax-advantaged payment option. According to IRS Publication 502, a prescription medication obtained from a licensed pharmacy generally qualifies as an eligible medical expense for these accounts.

Where Coverage Is Headed

Coverage for ketamine tablet is likely to broaden over time as FDA approval of an oral formulation becomes more plausible (several pharmaceutical development programs are underway), as some states introduce insurance mandates for ketamine coverage, as evidence accumulates in peer-reviewed literature, and as payer understanding of the mechanism improves. For a broader look at the coverage landscape, see our related piece on the oral ketamine tablet insurance coverage gap. For now, resolving a ketamine insurance claim denial takes persistence and documentation, but it isn't hopeless, particularly for pain indications and prescriber visit coverage.